Meningitis Outbreak Spawns Dicey Treatment Claims

by Patrick Malone & Associates P.C. | DC Injury Lawyers

Meningitis—a life-threatening inflammation of the membranes surrounding the brain and spinal cord—has seldom been more prominent in the news, and for all the wrong reasons. The contaminated steroid made and distributed by a compounding pharmacy has caused meningitis fatalities and widespread fear, and the story is developing daily.

So a warning letter sent by the FDA is particularly timely. As reported on, the letter was sent to Avalon Effect Inc., a company in Tennessee, because it has been advertising light emitting diodes (LED) to treat and cure the symptoms of fungal meningitis. In ghoulish exploitation, Avalon has targeted the people suffering from the disease they contracted from the dirty steroid injection.

The FDA letter warned Avalon Effect that the company’s Internet marketing information violates the Federal Food, Drug and Cosmetic Act.

Avalon claims that its Quantum Series Personal Wellness Pack, which promotes light therapy, treats and cures fungal meningitis, methicillin-resistant staphylococcus aureus (MRSA), concussions, Lyme disease and other ailments.

Yes, and it's a good overall pick-me-up nostrum, too. (Not!!!)

The FDA categorized the product as a medical device for treating and curing disease. Because such classification requires FDA approval prior to marketing, and because Avalon does not have that approval, it’s in violation of federal regulations.

Avalon has known for months that the FDA wanted it to clean up its act—the November warning letter is a follow-up to one sent in August, just as the meningitis outbreak was beginning.

The feds are not happy that a purported treatment for fungal meningitis that has not been approved or tested is being promoted purely for profit.

“Consumers should be aware that, especially during disease outbreaks or other public health crises, they may see opportunistic advertisements for products touted as cures or treatments,” said FDA official Steve Silverman in an agency news release. “Bogus medical claims can actually harm consumers by causing them to delay seeking treatments that have been proven to be safe and effective. Consumers should carefully evaluate and discuss the claims with their health care providers.”

Recent developments in the outbreak story include last week’s AP report that in 2002, the FDA advised that the New England Compounding Center (NECC), the outfit responsible for distributing the contaminated medicine, be “prohibited from manufacturing” because its operations were deemed shoddy. The feds deferred to Massachusetts state regulators, who reached an accommodation with the pharmacy to resolve those concerns. Now, you wonder, were they ever resolved? Were they temporarily resolved?

The meningitis outbreak also prompted a Congressional appearance by FDA Commissioner Margaret Hamburg last week. The committee wanted to know why the FDA hammer didn't fall harder on the NECC, and Hamburg said the agency's authority in the matter wasn't clear. The Democrats generally supported boosting FDA authority over compounding pharmacies, but Republicans said the agency has all the power it needs.

The Boston Globe reported that during Congressional hearings last week, Barry Cadden, the owner of the NECC, took the Fifth Amendment and declined to answer questions about the meningitis outbreak.

And, according to The Globe, it turns out that in 2002, Cadden was a member of a state task force charged with writing rules for compounding pharmacies at the same time NECC was being investigated by state and federal regulators. As the old saying goes, who guards the guards?


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patrick Malone & Associates P.C. | DC Injury Lawyers | Attorney Advertising

Written by:

Patrick Malone & Associates P.C. | DC Injury Lawyers

Patrick Malone & Associates P.C. | DC Injury Lawyers on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.